{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:44:05Z","timestamp":1761630245578},"reference-count":34,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2000,9,1]],"date-time":"2000-09-01T00:00:00Z","timestamp":967766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2000,9]]},"DOI":"10.1067\/mjd.2000.106515","type":"journal-article","created":{"date-parts":[[2002,7,25]],"date-time":"2002-07-25T04:15:48Z","timestamp":1027570548000},"page":"448-458","source":"Crossref","is-referenced-by-count":101,"title":["Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis"],"prefix":"10.1067","volume":"43","author":[{"given":"James G.","family":"Krueger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian B.","family":"Walters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megumi","family":"Miyazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Gilleaudeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Hakimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Light","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amelia","family":"Sherr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice B.","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1067\/mjd.2000.106515_bib1","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3181\/00379727-206-43737","article-title":"Regulation of the human interleukin-2\/inter-leukin-2 receptor system: a role for immunosuppression","volume":"206","author":"Kaempfer","year":"1994","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1067\/mjd.2000.106515_bib2","doi-asserted-by":"crossref","first-page":"10029","DOI":"10.1073\/pnas.86.24.10029","article-title":"A humanized antibody that binds to the interleukin 2 receptor","volume":"86","author":"Queen","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1067\/mjd.2000.106515_bib3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1089\/hyb.1985.4.91","article-title":"A monoclonal antibody, 7G7B6, binds to an epitope on the human interleukin-2 (IL-2) receptor that is distinct from that recognized by IL-2 or anti-TAC","volume":"4","author":"Rubin","year":"1985","journal-title":"Hybridoma"},{"key":"10.1067\/mjd.2000.106515_bib4","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/nm0595-442","article-title":"Response of psoriasis to a lymphocyte-selective toxin (DAB 389 IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis","volume":"1","author":"Gottlieb","year":"1995","journal-title":"Nature Med"},{"key":"10.1067\/mjd.2000.106515_bib5","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1084\/jem.164.4.1013","article-title":"Expression of HLA-DR molecules by keratinocytes and presence of Langerhans cells in the dermal infiltrate of active psoriatic plaques","volume":"164","author":"Gottlieb","year":"1986","journal-title":"J Exp Med"},{"key":"10.1067\/mjd.2000.106515_bib6","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1046\/j.1523-1747.1999.00749.x","article-title":"The majority of epidermal T cells in psoriasis vulgaris lesions produce type 1 cytokines IFN-\u03b3, IL-2 and TNF-\u03b1, defining TC1 CTL and TH1 effector populations: a type 1 differentiation bias is also measured in circulating T cells in psoriatic patients","volume":"113","author":"Austin","year":"1999","journal-title":"J Invest Dermatol"},{"key":"10.1067\/mjd.2000.106515_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/jaut.1999.0343","article-title":"CD69, HLA-DR and the IL-2R identify persistently activated T cells in psoriasis vulgaris lesional skin: blood and skin comparisons by flow cytometry","volume":"14","author":"Ferenczi","year":"2000","journal-title":"J Autoimmun"},{"key":"10.1067\/mjd.2000.106515_bib8","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJM199801153380304","article-title":"Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation","volume":"338","author":"Vincenti","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1067\/mjd.2000.106515_bib9","doi-asserted-by":"crossref","first-page":"7462","DOI":"10.1073\/pnas.96.13.7462","article-title":"Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I\/II clinical trial","volume":"96","author":"Nussenblatt","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1067\/mjd.2000.106515_bib10","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1182\/blood.V84.4.1320.1320","article-title":"Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor","volume":"84","author":"Anasetti","year":"1994","journal-title":"Blood"},{"key":"10.1067\/mjd.2000.106515_bib11","first-page":"315","article-title":"Pathogenic interactions of keratinocytes and T lymphocytes in psoriasis","author":"Krueger","year":"1998"},{"key":"10.1067\/mjd.2000.106515_bib12","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1172\/JCI5857","article-title":"CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris","volume":"103","author":"Abrams","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1067\/mjd.2000.106515_bib13","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/381434a0","article-title":"Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways","volume":"381","author":"Larsen","year":"1996","journal-title":"Nature"},{"key":"10.1067\/mjd.2000.106515_bib14","doi-asserted-by":"crossref","first-page":"13967","DOI":"10.1073\/pnas.93.24.13967","article-title":"Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection","volume":"93","author":"Hancock","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1067\/mjd.2000.106515_bib15","first-page":"679","article-title":"Phase 1 trial of psoriasis with an anti-CD11A (LFA-1) monoclonal antibody (MAB)","volume":"110","author":"Gottlieb","year":"1998","journal-title":"J Invest Dermatol"},{"key":"10.1067\/mjd.2000.106515_bib16","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/0167-5699(96)80599-8","article-title":"FK506 in the treatment of inflammatory skin disease: promises and perspectives","volume":"17","author":"Michel","year":"1996","journal-title":"Immun Today"},{"key":"10.1067\/mjd.2000.106515_bib17","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1073\/pnas.79.12.3848","article-title":"Possible metabolic basis for the different immunodeficient states assocated with genetic deficiencies of adenosine deaminase and purine nucleoside phosphorylase","volume":"79","author":"Carson","year":"1982","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1067\/mjd.2000.106515_bib18","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0190-9622(97)70147-6","article-title":"Rediscovering mycophenolic acid: a review of its mechanism, side effects, and potential uses","volume":"37","author":"Kitchin","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"10.1067\/mjd.2000.106515_bib19","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1006\/jaut.1997.0175","article-title":"Treatment of recalcitrant plaque psoriasis with a humanized non-depleting antibody to CD4","volume":"11","author":"Bachelez","year":"1998","journal-title":"J Autoimmun"},{"key":"10.1067\/mjd.2000.106515_bib20","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1172\/JCI119162","article-title":"Interferon-\u03b3 differentially regulates interleukin-12 and interleukin-10 production in leprosy","volume":"99","author":"Libraty","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1067\/mjd.2000.106515_bib21","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/00007890-199559040-00021","article-title":"Increased expression of IL-4 and IL-10 and decreased expression of IL-2 and interferon-\u03b3 in long-surviving mouse heart allografts after brief CD4-monoclonal antibody therapy","volume":"59","author":"Mottram","year":"1995","journal-title":"Transplantation"},{"key":"10.1067\/mjd.2000.106515_bib22","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1172\/JCI1476","article-title":"IL-10 is a key cytokine in psoriasis","volume":"101","author":"Asadullah","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1067\/mjd.2000.106515_bib23","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1172\/JCI6910","article-title":"Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions","volume":"104","author":"Trepicchio","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1067\/mjd.2000.106515_bib24","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/40166","article-title":"Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells","volume":"389","author":"Fuhlbrigge","year":"1997","journal-title":"Nature"},{"key":"10.1067\/mjd.2000.106515_bib25","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1182\/blood.V88.9.3259.bloodjournal8893259","article-title":"Selectins and their ligands: current concepts and controversies","volume":"88","author":"Kansas","year":"1996","journal-title":"Blood"},{"key":"10.1067\/mjd.2000.106515_bib26","doi-asserted-by":"crossref","first-page":"9282","DOI":"10.1073\/pnas.91.20.9282","article-title":"CD8+ T cells in psoriatic lesions preferentially use T-cell receptor V\u03b23 and\/or V\u03b213.1 genes","volume":"91","author":"Chang","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1067\/mjd.2000.106515_bib27","doi-asserted-by":"crossref","first-page":"690","DOI":"10.4049\/jimmunol.131.2.690","article-title":"Blockade of the interleukin-2 receptor by anti-Tac antibody: inhibition of human lymphocyte activation","volume":"131","author":"Depper","year":"1983","journal-title":"J Immunol"},{"key":"10.1067\/mjd.2000.106515_bib28","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1073\/pnas.88.7.2663","article-title":"Anti-Tac-H, a humanized antibody to the interleukin-2 receptor, prolongs primate cardiac allograft survival","volume":"88","author":"Brown","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1067\/mjd.2000.106515_bib29","doi-asserted-by":"crossref","first-page":"452","DOI":"10.4049\/jimmunol.158.1.452","article-title":"Humanized antibodies against the \u03b1-chain of the IL-2 receptor and against the \u03b2-chain shared by the IL-2 and IL-15 receptors in a monkey uveitis model of autoimmune diseases","volume":"158","author":"Guex-Crosier","year":"1997","journal-title":"J Immunol"},{"key":"10.1067\/mjd.2000.106515_bib30","first-page":"28","article-title":"Prolongation of primate renal allografts with anti-Tac monoclonal antibody","volume":"45","author":"Reed","year":"1988","journal-title":"Curr Surg"},{"key":"10.1067\/mjd.2000.106515_bib31","first-page":"451","article-title":"Anti-interleukin-2 receptor monoclonal anti-body (BT 563) in the treatment of severe acute GVHD refractory to systemic corticosteroid therapy","volume":"10","author":"Cuthbert","year":"1992","journal-title":"Bone Marrow Transplant"},{"issue":"Suppl 2","key":"10.1067\/mjd.2000.106515_bib32","first-page":"207","article-title":"Cyclosporine potentiates the immunosuppressive effects of anti-interleukin 2 receptor monoclonal anti-body therapy","volume":"20","author":"Kupiec-Weglinski","year":"1988","journal-title":"Transplant Proc"},{"issue":"Suppl 2","key":"10.1067\/mjd.2000.106515_bib33","first-page":"202","article-title":"Synergy with other agents in vitro and in vivo: synergistic interaction of cyclosporine A with interleukin 2 receptor monoclonal antibody therapy","volume":"20","author":"Tellides","year":"1988","journal-title":"Transplant Proc"},{"key":"10.1067\/mjd.2000.106515_bib34","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1001\/archderm.134.5.595","article-title":"Consensus workshop on the toxic effects of long-term PUVA therapy","volume":"134","author":"Morison","year":"1998","journal-title":"Arch Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962200686784?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962200686784?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T14:43:16Z","timestamp":1680532996000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962200686784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,9]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2000,9]]}},"alternative-id":["S0190962200686784"],"URL":"https:\/\/doi.org\/10.1067\/mjd.2000.106515","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2000,9]]}}}